Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer. In addition, the company is developing EZM8266, a G9a inhibitor that is in the Phase 1 study for the treatment of sickle cell disease; pinometostat, which is in the preclinical studies stage for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor that is in Phase II clinical trial for patients with solid tumors and NHL; and PRMT1 inhibitor, which is in the Phase 1 clinical trial. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Study Association; and Eisai Co. Ltd. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-229-5872
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$21.70 million
Profitability
Miscellaneous
Employees124
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Epizyme (NASDAQ:EPZM) Frequently Asked Questions
What is Epizyme's stock symbol?
Epizyme trades on the NASDAQ under the ticker symbol "EPZM."
How were Epizyme's earnings last quarter?
Epizyme Inc (NASDAQ:EPZM) announced its earnings results on Tuesday, February, 26th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.46) by $0.17. View Epizyme's Earnings History.
When is Epizyme's next earnings date?
What price target have analysts set for EPZM?
8 brokers have issued twelve-month price targets for Epizyme's stock. Their forecasts range from $11.00 to $25.00. On average, they anticipate Epizyme's share price to reach $18.50 in the next year. This suggests a possible upside of 51.5% from the stock's current price. View Analyst Price Targets for Epizyme.
What is the consensus analysts' recommendation for Epizyme?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme.
Has Epizyme been receiving favorable news coverage?
News headlines about EPZM stock have trended very negative on Thursday, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Epizyme earned a news impact score of -3.6 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.
Are investors shorting Epizyme?
Epizyme saw a increase in short interest in the month of February. As of February 15th, there was short interest totalling 5,712,083 shares, an increase of 31.5% from the January 31st total of 4,345,330 shares. Based on an average trading volume of 775,401 shares, the days-to-cover ratio is presently 7.4 days. Currently, 9.9% of the company's shares are sold short. View Epizyme's Current Options Chain.
Who are some of Epizyme's key competitors?
Some companies that are related to Epizyme include Amneal Pharmaceuticals (AMRX), Taro Pharmaceutical Industries (TARO), TESARO (TSRO), HUTCHISON CHINA/S (HCM), Agios Pharmaceuticals (AGIO), ACADIA Pharmaceuticals (ACAD), Blueprint Medicines (BPMC), Evotec (EVTCY), Ultragenyx Pharmaceutical (RARE), Intercept Pharmaceuticals (ICPT), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT), Reata Pharmaceuticals (RETA), Akcea Therapeutics (AKCA) and Mirati Therapeutics (MRTX).
What other stocks do shareholders of Epizyme own?
Who are Epizyme's key executives?
Epizyme's management team includes the folowing people:
- Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 51)
- Mr. Matthew E. Ros, Chief Strategy & Bus. Officer and Principal Financial Officer (Age 52)
- Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
- Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
- Mr. Joseph Beaulieu, Controller, Treasurer & Principal Accounting Officer (Age 38)
Who are Epizyme's major shareholders?
Epizyme's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (8.69%), BlackRock Inc. (6.56%), FMR LLC (4.39%), Jennison Associates LLC (2.37%), Foresite Capital Management II LLC (1.97%) and Norges Bank (1.43%). Company insiders that own Epizyme stock include Andrew E Singer, David M Mott, Matthew Ros, Peter Tai-Ching Ho and Robert A Copeland. View Institutional Ownership Trends for Epizyme.
Which institutional investors are selling Epizyme stock?
EPZM stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, Tekla Capital Management LLC, Eversept Partners LP, New York State Common Retirement Fund, MetLife Investment Advisors LLC and Barclays PLC. View Insider Buying and Selling for Epizyme.
Which institutional investors are buying Epizyme stock?
EPZM stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Opaleye Management Inc., BlackRock Inc., Millennium Management LLC, NEA Management Company LLC, Sphera Funds Management LTD., Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. View Insider Buying and Selling for Epizyme.
How do I buy shares of Epizyme?
Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Epizyme's stock price today?
One share of EPZM stock can currently be purchased for approximately $12.21.
How big of a company is Epizyme?
Epizyme has a market capitalization of $1.11 billion and generates $21.70 million in revenue each year. The biopharmaceutical company earns $-123,630,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Epizyme employs 124 workers across the globe.
What is Epizyme's official website?
How can I contact Epizyme?
Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]
MarketBeat Community Rating for Epizyme (NASDAQ EPZM)
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.
